bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim
- Wall Street gains, helped by oil, economic data
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Unusual 11 Mid-Day Movers 12/5: (NVCN) (BCEI) (MEMP) Higher; (GTXI) (CERC) (HDSN) Lower
- Oil hits 16-month high in buying rush after OPEC agreement
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of bluebird bio (NASDAQ: BLUE) after Mast Therapeutics' (NASDAQ: MSTX) phase III study (EPIC) of vepoloxamer failed to show efficacy over the placebo.
The analyst considered the problem of what could be done to treat the pain and determined that a cure (via gene therapy) may be the best method. Gene therapy with bluebird's LentiGlobin in just two patients has suggested that targeting the "source" of disease could potentially represent a "cure." The question now is how many patients represent proof of concept (POC), and would the sickle cell community adopt gene therapy? Answering the question will take more patients and more time but the analyst is expecting data from multiple patients at ASH in December.
No change to the price target of $85.
Shares of bluebird bio closed at $73.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- High VCN Number at ASH Bodes Well for bluebird bio (BLUE) - Maxim Group
- Mizuho Securities Raises Price Target on PDC Energy (PDCE) to $81; Reiterates Neutral
- bluebird bio (BLUE) Presents New Data on LentiGlobin HGB-205 Study at ASJ 2016
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesMaxim Group
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!